Merrimack Pharmaceuticals Announces the Addition of Former Deloitte Global CEO James H. Quigley to Its Board of Directors
Quigley recently retired as a Senior Partner with
"Jim's experience as a leader in a global firm and his expertise in financial reporting make him a fantastic addition to Merrimack as we advance our portfolio of oncology therapeutics and diagnostics and continue to build an innovative, global medicine company," said
Quigley earned a Bachelor of Science degree and an honorary Doctorate of Business from
"I am delighted to join the Merrimack Board and appreciate the privilege of working with Gary and the other Board members. I look forward to supporting and guiding the management team in pursuit of Merrimack's ambitious mission to transform drug development in a way that will offer patients and physicians better treatment options and outcomes," said Quigley.
Merrimack also announced today the resignation of
"Bob's expertise has been a great asset to Merrimack. We are grateful for the guidance and support he has offered during his tenure on our Board," said
Quigley joins Board members
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.
Forward-looking statements
Any statements in this press release about Merrimack's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT:Source:Kathleen Petrozzelli Gallagher , Corporate Communications Merrimack 617-441-1043 kgallagher@merrimackpharma.comBetsy Stevenson RaymondStevenson Healthcare Communications 860-984-1424 betsy@raymondstevenson.com
News Provided by Acquire Media